Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Malignant Neoplasm: early-phase trial registry
1 of 11 indexed Recurrent Malignant Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 1 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Recurrent Malignant Neoplasm: 11 US clinical trials tracked, 1 recruiting.
Recurrent Malignant Neoplasm is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 9 of these trials.
Enrollment posture brief
Registry condition recurrent-malignant-neoplasm
OPEN 1 | RECR 9% | LATE 1 | EARLY 5 | RANK #1577 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Advanced Cancers (9% recruiting · 11 trials)
Recurrent Malignant Neoplasm lists 1 open slots (9% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Malignant Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Malignant Neoplasm is recruiting below its size-band peers.
1 of 11 indexed trials (9.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Malignant Neoplasm research.
M.D. Anderson Cancer Center accounts for 9 of 11 trials (81.8%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical Recurrent Malignant Neoplasm enrolment sits around 141 participants.
Median target enrolment is 141 among the 11 trials that report a genuine target (sentinel values excluded). 3 of those (27.3%) plan for fewer than 100 participants.
-
Recurrent Malignant Neoplasm splits between interventional and observational designs.
7 interventional and 4 observational studies make up this index (63.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Children's Oncology Group
NCT01790152
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
M.D. Anderson Cancer Center
NCT02152254
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
M.D. Anderson Cancer Center
NCT03525873
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
M.D. Anderson Cancer Center
NCT02286687
Financial Distress in Advanced Cancer Patients
M.D. Anderson Cancer Center
NCT04053517
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
M.D. Anderson Cancer Center
NCT03743649
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
NCT02491632
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
M.D. Anderson Cancer Center
NCT03021486
Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
M.D. Anderson Cancer Center
NCT04186884
Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits
M.D. Anderson Cancer Center
NCT03856060
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
University of California, San Francisco
NCT04409314
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Malignant Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Malignant Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Malignant Neoplasm page
11 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Malignant Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Recurrent Malignant Neoplasm trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Malignant Neoplasm condition card totals 11 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.